Table 2. Association of ASPM expression levels with different clinicopathologic characteristics in serous adenocarcinoma.
| Clinicopathologic | ASPM expression, n (%) | P value | |
|---|---|---|---|
| Low count | High count | ||
| Age, years | 0.554 | ||
| ≤50 | 13 (59.1) | 10 (50.0) | |
| >50 | 9 (40.9) | 10 (50.0) | |
| Lymph node metastasis | 0.043 | ||
| N0 | 22 (100.0) | 15 (75.0) | |
| N1 | 0 (0.0) | 5 (25.0) | |
| TNM stage | 0.002 | ||
| Stage I | 18 (81.9) | 7 (35.0) | |
| Stage II | 1 (4.5) | 0 (0.0) | |
| Stage III | 3 (13.6) | 13 (65.0) | |
| Histologic grade | 0.015 | ||
| Grade 1 | 7 (31.8) | 0 (0.0) | |
| Grade 2 | 4 (18.2) | 3 (15.0) | |
| Grade 3 | 11 (50.0) | 17 (85.0) | |
P values were calculated by comparing the expression of ASPM with different clinical variables respectively using a chi-square test. P<0.05 was considered statistically significant. ASPM, spindle-like microcephaly-associated protein; TNM, tumor-node-metastasis.